JBA AI, the flagship digital health division of AQ Pharmaceuticals and JBA Brands, has achieved a major milestone with official recognition from the U.S. FDA as a Software as a Medical Device (SaMD), alongside Class B Medical Device approval from Vietnam’s Ministry of Health. These dual regulatory endorsements validate the platform’s clinical credibility and global readiness, marking a significant step forward in accessible, AI-driven preventive healthcare. Designed to run on smartphones and tablets, JBA AI eliminates the need for specialized hardware, making advanced health monitoring more affordable and scalable than traditional tools.

The JBA AI mobile app utilizes remote photoplethysmography technology powered by artificial intelligence to analyze facial signals captured by a device’s camera. In just 60 seconds, users can receive insights into over nine vital health metrics, including heart rate, respiratory rate, blood oxygen saturation, heart rate variability, stress index, and estimated glucose and blood pressure trends—all without needles, wearables, or clinic visits. Already available on Android and soon launching on iOS, the app delivers clinically guided, contactless monitoring suitable for use at home, in pharmacies, corporate wellness programs, and public health campaigns.

With support from a major Vietnamese financial institution serving over 30 million people, JBA AI is poised for nationwide rollout in Vietnam. Its franchise-ready model allows for rapid, low-cost deployment across global markets, reinforcing its mission to make preventive health monitoring more intelligent, accessible, and inclusive. The dual recognition by U.S. and Vietnamese authorities positions JBA AI as a transformative force in digital health—empowering individuals and healthcare systems alike with real-time, AI-enhanced insights that support proactive, data-driven wellness.